SARS-CoV-2 – COVID-19 Vaccine Research Tools

Covid-19 is caused by the coronavirus, SARS-CoV-2. The Spike protein (S), a structural protein on the surface of the CoV, mediates the interaction between the SARS-CoV-2 and Human cell via ACE2. Nucleocapsid (N) is a structural protein that holds the +RNA viral genome. Both the S protein and N proteins of SARS-CoV-2 are the leading target antigens in COVID-19 vaccine developments. Vigene provides S and N proteins in adenovirus, AAV and pseudotyped lentivirus that could be valuable for COVID-19 research and vaccine developments.

See All SARS-CoV-2 Vaccine Research Tools >

Watch the COVID-19 Vaccine Research Tools webinar >>

Spike-Pseudotyped Integration Deficient (IDLV) Lentivirus - SARS-CoV-2 Vaccine Research Tools

Spike-Pseudotyped lentiviral particles are packaged using the spike protein from SARS-CoV-2 as the envelope protein instead of the regular VSV-G as the envelop glycoprotein. Spike protein expression on the surface of the virus enables the interaction with ACE2 receptor on the host cells. S-pseudotyped lentivirus can be used to generate spike specific antibodies, SARS-CoV-2 and ACE2 interaction studies, and can be used for SARS-CoV-2 neutralizing antibody screenings. Vigene offers two types of S-pseudotyped lentiviruses, one with Spike protein in the RNA viral genome, another one with GFP in the RNA viral genome.

The pseudo lentiviral particles are packaged using integration deficient packaging plasmids, so the lentiviruses are integration deficient (IDLV), which prevent incorporation into the host genome.

Spike-Pseudotyped integration deficient lentivirus (IDLV) containing S protein of SARS-CoV-2

In this S-pseudotyped lentivirus, codon optimized S protein of SARS-CoV-2 is packaged in the lentiviral genome, providing additional antigens to enhance the immune responses against SARS-CoV-2.

Features
  • S protein on the surface of the pseudo lentivirus
  • S protein (codon optimized), also packaged in the lentivirus, providing additional antigens to enhance the immune responses against SARS-CoV-2
  • Induced high level of Spike specific antibodies in mice
  • Replication deficient lentiviruses
  • No integration into the host genome as the vector is integration deficient
  • Production only needs BSL2 biosafety level
Applications
  • SARS-CoV-2 vaccine research – Non-integrating Spike-Pseudotyped lentiviral vector
  • Non-virulent antigen for COVID neutralizing antibody generation
Applications
  • SARS-CoV-2 vaccine research – Non-integrating Spike-Pseudotyped lentiviral vector
  • Non-virulent antigen for COVID neutralizing antibody generation

CAT# Product Description Availability Price
COV-LENTI-S S-pseudotyped IDLV Lentivirus (Spike Protein)

Ultra-purified Spike-Pseudotyped lentivirus containing S protein of SARS-CoV-2, integration deficient, >109 IFU/mL, 4 x 25 uL

In stock $1,500

Spike-Pseudotyped lentiviruses potently induced antibodies specific to S protein in mice

Trulli
Fig. 1. Spike-Pseudotyped lentiviruses containing S protein gene of SARS-CoV-2 were injected intraperitoneally into Balb/C mice, 7.8x105 IFU/mouse (left panel) and 3.88x106 IFU/mouse (right panel). The serum samples from day 0, 7, 14, 21 and 28 days after immunization were tested by ELISA to detect SARS-CoV-2 spike protein specific antibodies.
Spike-Pseudotyped IDLV Lentivirus Containing GFP Reporter

Spike-Pseudotyped lentiviral particles are packaged using the spike protein from SARS-CoV-2 as the envelope protein instead of the regular VSV-G as the envelop glycoprotein. S protein expression on the surface of the virus enables the interaction with ACE2 receptor on the host cells. GFP reporter is packaged in the pseudotyped lentiviral genome.

The pseudo lentiviruses are packaged using integration deficient packaging plasmids, so the viral genome won’t integrate into the host genome.

Features
  • GFP is packaged in the pseudo lentivirus
  • Integrating deficient lentiviruses
  • Potent SARS-CoV-2 vaccine research tool, but without SARS-CoV-2 genetic materials, similar to VLP vaccines
  • Induced strong SARS-CoV-2 S-specific antibodies in mice
Applications
  • A great tool for SARS-CoV-2 antibody neutralizing antibody screening
  • Research tool for interaction between SARS-CoV-2 with ACE2 receptors
  • Better antigen for SARS-CoV-2 Spike protein neutralizing antibody generation
  • Potent SARS-CoV-2 vaccine research tool

CAT# Product Description Availability Price
COV-LENTI-GFP S-Pseudotyped IDLV lentivirus (GFP)

Ultra-purified Spike-Pseudotyped lentivirus containing eGFP, integration deficient, >109 IFU/mL, 4 x 25 uL

In stock $1,500

Spike-Pseudotyped lentivirus (GFP reporter) can potently induce Spike protein specific antibodies in mice

Trulli
Fig. 2. Spike-Pseudotyped lentiviruses (GFP reporter) were injected into Balb/C mice intraperitoneally, 7.6x105 IFU/mouse (left panel) and 3.78x106 IFU/mouse (right panel). Serum samples from day 0, 7, 14, 21, and 28 days after immunization were tested by ELISA to detect SARS-CoV-2 spike specific antibodies.

Diagram of how IDLV spike-pseudotyped lentivirus is packaged and its transduction

Diagram of using Spike-Pseudotyped lentivirus (GFP reporter) for SARS-CoV-2 antibody neutralization assays

adeno x

Adenovirus - SARS-CoV-2 Vaccine Research Tools

Adenovirus Expressing Spike Protein or Nucleocapsid of SARS-CoV-2

Recombinant adenoviral vectors are commonly used to develop vaccines against infectious viruses. Vigene produced Ad5 recombinant virus encoding SARS-CoV-2 Spike protein or Nucleocapsid Protein. AD5 expressing SARS-CoV-2 S protein have been tested to robustly produce S protein specific antibodies in immunized mice.

Features
  • Recombinant adenovirus, replication deficient
  • Adenovirus expressing SARS-CoV-2 Spike protein
  • Adenovirus expressing SARS-CoV-2 Nucleocapsid
  • COVID neutralizing antibody generation
  • Potential SARS-CoV-2 vaccine research tools

CAT# Product Description Availability Price
COV-AD-S Adenovirus (SARS-CoV-2 Spike)

Adenovirus type 5 expressing SARS-CoV-2 Spike and CopGFP, >1x1012 VP/mL, 2 x 250 uL

In stock $1,500
COV-AD-N Adenovirus (SARS-CoV-2 Nucleocapsid)

Adenovirus type 5 expressing SARS-CoV-2 Nucleocapsid and CopGFP, >1x1012 VP/mL, 2 x 250 uL

In stock $1,500

Adenovirus type 5 (SARS-CoV-2 Spike) can potently induce Spike protein specific antibodies in mice

Trulli
Fig. 3. Adenovirus type 5 encoding SARS-CoV-2 Spike Protein were injected into Balb/C mice intraperitoneally , 1.5x109 VP/mouse (left panel) and 7.5x109 VP/mouse (right panel). Serum samples from day 0, 7, 14 and 28 days after immunization were tested by ELISA to detect SARS-CoV-2 spike antibodies.

AAV - SARS-CoV-2 Vaccine Research Tools

AAV9 expressing S protein of SARS-CoV-2 or S1 subunit

Adeno associated virus (AAV) is a commonly used gene therapy viral vector. Vigene produced AAV9 recombinant virus encoding SARS-CoV-2 Spike protein or S1 subunit that can be used as SARS-CoV-2 vaccines. AAV9 (SARS-CoV-2 S1 subunit) viral vectors have been tested to robustly produce S protein specific antibodies in mice.

Features
  • AAV9 encoding S protein of SARS-CoV-2
  • AAV9 encoding S1 subunit of SARS-CoV-2
  • S1 subunit is engineered for membrane expression on host cell
  • Great tools for SARS-CoV-2 neutralizing antibody generation
  • Potential SARS-CoV-2 vaccine research tools

CAT# Product Description Availability Price
COV-AV-S AAV9 (SARS-CoV-2 Spike)

AAV9 encoding SARS-CoV-2 Spike Protein, >1x1013 GC/mL, 2 x 250 uL

In stock $1,500
COV-AV-S1 AAV9 (SARS-CoV-2 Spike, S1 domain)

AAV9 encoding SARS-CoV-2 S1 subunit, designed to be expressed on host cell membrane, , >1x1012 GC/mL, 2 x 250 uL

In stock $1,500

AAV9 (SARS-CoV-2 S1 subunit) can potently induce Spike protein specific antibodies in mice

Trulli
Fig. 4. AAV9 encoding SARS-CoV-2 S1 subunit were injected into Balb/C mice intraperitoneally, 8.24x107 GC/mouse (left panel) and 4.12x108 GC/mouse (right panel). Serum samples from day 0, 7, 14 and 28 days after immunization were tested by ELISA to detect SARS-CoV-2 spike antibodies.

SARS-CoV-2 Products Disclaimer:

Products are for research use only. Vigene Biosciences’ products are to be used for research purposes only. They may not be used for any other purposes, including, but not limited to, in vitro diagnostic purposes, therapeutics, or in humans.

adeno x

6 Items

per page
Set Descending Direction
  1. AAV9 (SARS-CoV-2 Spike)
    COV-AV-S
    pAV-CMV-S
    CMV
  2. AAV9 (SARS-CoV-2 Spike, S1 domain)
    COV-AV-S1
    pAV-CMV-S1
    CMV
  3. Adenovirus (SARS-CoV-2 Nucleocapsid)
    COV-AD-N
    pAD-CMV-S-mCMV-copGFP
    CMV
  4. Adenovirus (SARS-CoV-2 Spike)
    COV-AD-S
    pAD-CMV-N-mCMV-copGFP
    CMV
  5. S-Pseudotyped IDLV lentivirus (GFP)
    COV-LENTI-GFP
    Spike protein of SARS-CoV-3
    eGFP
    Yes
  6. S-pseudotyped IDLV Lentivirus (Spike Protein)
    COV-LENTI-S
    Spike protein of SARS-CoV-2
    Spike RNA of SARS-CoV-2
    Yes

6 Items

per page
Set Descending Direction

Covid-19 is caused by the coronavirus, SARS-CoV-2. The Spike protein (S), a structural protein on the surface of the CoV, mediates the interaction between the SARS-CoV-2 and Human cell via ACE2. Nucleocapsid (N) is a structural protein that holds the +RNA viral genome. Both the S protein and N proteins of SARS-CoV-2 are the leading target antigens in COVID-19 vaccine developments. Vigene provides S and N proteins in adenovirus, AAV and pseudotyped lentivirus that could be valuable for COVID-19 research and vaccine developments.